(redirected from Polyvinylpyrrolidone)
Also found in: Medical, Acronyms, Wikipedia.


A polymer used as a vehicle for a drug, especially iodine.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
[ClickPress, Fri Aug 30 2019] Innate combination of exceptional physical and chemical properties, including non-toxicity, biocompatibility, chemical stability and good solubility in water and other organic solvents have made polyvinylpyrrolidone (PVP) ideal as a biomaterial in several medical and non-medical applications.
Global polyvinylpyrrolidone market is anticipated to expand at a significant CAGR in the upcoming period as the scope, product types, and its applications are increasing across the globe.
The prepared sperm was diluted 1:1 with 12% polyvinylpyrrolidone in PBS immediately, just before microinjection.
The cyst cavities were irrigated with hypertonic saline solution and polyvinylpyrrolidone, and then filled with bone allograft.
Polyvinylpyrrolidone K30 (PVP) was used to increase the adhesive of Eudragit polymers [9].
When polyvinylpyrrolidone was used to inhibit polyphenol oxidase activity, the yield and integrity of RNA had improved significantly.
bromide (CTAB) extraction buffer (2% CTAB, 5M NaCl, 2% polyvinylpyrrolidone (PVP), 0.5M ethylene diamine tetra acetic acid (EDTA) pH 8, Tris- HCL (Trizma base HCl) pH 8 and 2% b-mercaptoethanol in a centrifuge tube.
An aqueous solution (B) of sodium lauryl sulphate (2 g) in distilled water (20 ml) was added drop-wise with magnetic stirring to the organic phase (A) obtained by mixing the solution of polyvinylpyrrolidone (PVP) (2 g) in dichloromethane (20 ml) with the solution of technical grade larvicide (0.5 g) in dichloromethane (20 ml) to yield a stable emulsion.
Dried samples were ground in five volumes of phosphate buffered saline containing polyvinylpyrrolidone (1%) and bovine serum albumin (0, 1%).
To increase platinum deposition the dispersing agent polyvinylpyrrolidone (PVP) has been used with a concentration of 0.001 M [2].
It consists of driver cobalt chromium stent platform and 3 different polymers: hydro-phobic C10 polymer to control drug release; biocompatible and hydrophilic C19 polymer; and polyvinylpyrrolidone. This polymer provides 85% of drug release in 60 days and the remaining in 180 days (36).